TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Brokerages

Key Points

• Analyst consensus: "Hold" — Six analysts cover TCRX (1 sell, 2 hold, 3 buy) with an average 12-month price target of $6.00.
• Shares trade cheaply vs. target and company is unprofitable — TCRX opened near $1.22 (1-year range $0.88–$2.57) with a market cap of about $69M; it beat quarterly EPS (-$0.18 vs. -$0.27) but remains unprofitable and analysts expect -$1.02 EPS for the year.
• High institutional ownership — Hedge funds and other institutional investors own 82.83% of the company, with several small new stakes and increases reported recently.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has earned a consensus recommendation of "Hold" from the six research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $6.00.

A number of equities analysts have recently commented on TCRX shares. Wedbush lifted their target price on TScan Therapeutics from $4.00 to $5.00 and gave the stock an "outperform" rating in a report on Thursday, March 5th. Wall Street Zen cut TScan Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 14th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of TScan Therapeutics in a report on Tuesday, April 21st.

Hedge Funds Weigh In On TScan Therapeutics

Large investors have recently bought and sold shares of the business. Panagora Asset Management Inc. purchased a new position in TScan Therapeutics during the 4th quarter valued at $25,000. HRT Financial LP purchased a new position in TScan Therapeutics during the 4th quarter valued at about $26,000. Boothbay Fund Management LLC raised its holdings in shares of TScan Therapeutics by 50.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company's stock valued at $35,000 after purchasing an additional 8,121 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in shares of TScan Therapeutics in the 1st quarter valued at about $63,000. Finally, Marshall Wace LLP purchased a new stake in shares of TScan Therapeutics in the 2nd quarter worth approximately $78,000. Hedge funds and other institutional investors own 82.83% of the company's stock.

TScan Therapeutics Stock Performance

NASDAQ:TCRX opened at $1.22 on Tuesday. The company has a market cap of $69.42 million, a price-to-earnings ratio of -1.22 and a beta of 1.06. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.41 and a quick ratio of 8.41. The stock's 50 day simple moving average is $1.10 and its two-hundred day simple moving average is $1.18. TScan Therapeutics has a 1 year low of $0.88 and a 1 year high of $2.57.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its earnings results on Wednesday, March 4th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.09. The firm had revenue of $2.57 million during the quarter, compared to analysts' expectations of $2.44 million. TScan Therapeutics had a negative return on equity of 79.36% and a negative net margin of 1,256.81%. As a group, equities analysts anticipate that TScan Therapeutics will post -1.02 earnings per share for the current fiscal year.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan's approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company's pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.